Not logged in.png)
Share.png)
SaveShare Save Share Save A risk-adjusted CUSUM for monitoring the surgical quality reflected by the time-to-event outcomes with a cured fraction
Liu, Ruoyu; Huang, Jiangrui; Lai, Xin; Wang, Jiayin; Zhu, Xiaoyan; Liu, Yuqian; Yang, Shuanying; Lai, Paul B. S.; Cheung, Sunny Yue Sun; Chong, Ka Chun Share Save Share Save Share Save Share Save TMBocelot: an omnibus statistical control model optimizing the TMB thresholds with systematic measurement errorsLai, Xin; Wang, Shaoliang; Zhang, Xuanping; Zhu, Xiaoyan; Liu, Yuqian; Chang, Zhili; Wang, Xiaonan; Shao, Yang; Wang, Jiayin; Wang, Yixuan Share Save THOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured dataWang, Yixuan; Guan, Yanfang; Lai, Xin; Liu, Yuqian; Chang, Zhili; Wang, Xiaonan; Wang, Quan; Liu, Jingjing; Zhao, Jian; Yang, Shuanying; Wang, Jiayin; Song, Xiaofeng Share Save Share Save Share Save Share Save Share Save What makes TMB an ambivalent biomarker for immunotherapy? A subtle mismatch between the sample-based design of variant callers and real clinical cohortLiu, Yuqian; Wang, Shenjie; Wang, Yixuan; Li, Yifei; Zhu, Xiaoyan; Lai, Xin; Zhang, Xuanping; Li, Xuqi; Xiao, Xiao; Wang, Jiayin Share Save Share Save TMBcat: A multi-endpoint p-value criterion on different discrepancy metrics for superiorly inferring tumor mutation burden thresholdsWang, Yixuan; Lai, Xin; Wang, Jiayin; Xu, Ying; Zhang, Xuanping; Zhu, Xiaoyan; Liu, Yuqian; Shao, Yang; Zhang, Li; Fang, Wenfeng Share Save Share Save Share Save Share Save Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
